Merck is granted rights to Xencor's monoclonal antibody patent

07/3/2013 | Genetic Engineering & Biotechnology News

Merck & Co. secured nonexclusive licensing rights to one of Xencor's engineering patents for a monoclonal antibody. The deal allows Merck to use the patent for an undisclosed product and gives it an option to license the same patent for future products. Xencor is entitled to an upfront payment, yearly maintenance fees and potential milestone payments and sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel
Cardinal Health
Columbus, OH
Regulatory Affairs Specialist
Stryker
Mahwah, NJ
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA